1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

Dutch Competition Body Urged To Fine Leadiant Over 'Exorbitant' Orphan Drug Price

 
• By Ian Schofield

The Dutch Pharmaceutical Accountability Foundation has asked the country's competition authority to take action against Leadiant Biosciences over the company's pricing of an orphan drug for a rare genetic disease. 

SC1711_Purse-Pills_673872868_1200
Leadiant is accused of charging too much for its CTX drug

The new Dutch foundation that has criticized the pricing of Leadiant’ Biosciences’ orphan drug CDCA on Sept. 7 will file a formal request with the Dutch competition authority asking it to either fine the company or take some other action over what it calls the “exorbitant price the company is asking.”

Leadiant’s CDCA product, which has EU approval for the treatment of the rare genetic disease cerebrotendinous xanthomatosis (CTX), is currently...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Could MFN Pricing Impact Commercial Market?

 
• By Angela Maas

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.

More from Market Access

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

 
• By Sarah Karlin-Smith

The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

How Could MFN Pricing Impact Commercial Market?

 
• By Angela Maas

Industry experts forecast the impact of President Trump's Most-Favored Nation drug pricing policy on the commercial insurance industry.